Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
Authors not listed
Beijing Immunochina Medical Science & Technology Co., Ltd. · 2020
Abstract
This is a single center study to assess the efficacy and safety of IM21 CAR-T cells in adult with R/R multiple myeloma in China.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-10-19 MST
Cite this
APA
Anonymous. (2020). Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma. <em>Beijing Immunochina Medical Science & Technology Co., Ltd.</em>. https://clinicaltrials.gov/study/NCT04537442
Vancouver
Anonymous. Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma. Beijing Immunochina Medical Science & Technology Co., Ltd.. 2020.
BibTeX
@misc{anon2020Clinic,
title = {Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma},
author = {Anonymous},
journal = {Beijing Immunochina Medical Science & Technology Co., Ltd.},
year = {2020},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
The First Affiliated Hospital with Nanjing Medical University 2012
Open access · US-GOV
A Prospective, Single-arm, Open-label, Phase 2 Study to Evaluate Efficacy and Safety of R-GemOx Regimen as First-line Treatment in Elderly Patients With Diffuse Large B-cell Lymphoma (DLBCL).
UNC Lineberger Comprehensive Cancer Center 2023
Open access · US-GOV
Study of Isatuximab Plus Pomalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Relapsed or Refractory Multiple Myeloma
Janssen-Cilag G.m.b.H 2006
Open access · US-GOV
Consolidation Therapy With Bortezomib in Patients With Multiple Myeloma Aged 61 to 75
Leukemia 2007
Preprint · OA
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma
Hexun Biosciences Co., LTD. 2026
Open access · US-GOV
A Phase I, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of HeXell-2020 Administered Intravenously in Elderly Subjects With Mild to Moderate Frailty Syndrome
Meribank Biotech Co., Ltd. 2024
Open access · US-GOV